

**DRUG RECALL – Type III – URGENT**

**Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag)**

**Lots: 440228 00125 & 440228 00135**

**Exp: 04/30/2028**

Date: February 5, 2026

Risk Classification: **Type III Recall**

Drug: Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag)

Product Code: CP1455B1

DIN: 02401029

Distributed Lots: 440228 00125 and 440228 00135

Expiry Date: 04/2028

Dear Customer/Healthcare Professional,

Fresenius Kabi Canada would like to inform you of our decision to recall Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag), lots: 440228 00125 and 440228 00135.

This recall is being performed as an incorrect GTIN was printed and encoded into the 2D barcode on both the inner and outer bag labels. The printed GTIN and 2D barcode correspond to Ceftriaxone (CP1456B1). Health Canada has been informed of this issue and is aware of the recall proceedings.

We request that you examine your inventory immediately to determine if you have any of the affected lot numbers on hand. If yes, discontinue use and distribution of the affected lots immediately.

**Please complete the Customer Reply Form provided below as soon as possible, and return it to Fresenius Kabi Canada via the provided email address. A reply is requested within 24 hours of receipt of this communication.**



Affected units should be returned to your point of purchase. Affected units purchased directly from Fresenius Kabi Canada should be returned to the following site:

Fresenius Kabi Canada Ltd.  
c/o Accuristix  
100 Vaughan Valley Blvd,  
Vaughan, ON  
L4H 3C5

A Returned Goods Authorization (RGA) number is required to return units purchased directly from Fresenius Kabi Canada, which will be issued by Fresenius Kabi Canada Customer Service upon receipt of a completed Customer Reply Form. For pick-up of product to be returned, please contact ATS at 1-877-694-4454 and utilize Account Number 4005154 for return of the product. Note, all boxes being returned should have the RGA number clearly listed on the exterior.

Please ensure that every user of the concerned products within your organization and all other relevant persons or entities to whom the concerned products have been transferred are informed about this letter and the actions described herein.

If you experience an adverse reaction with respect to this occurrence, please contact Fresenius Kabi Canada Vigilance department and identify the product and lot associated with the incident. Adverse reactions experienced with the use of this product should be reported to Fresenius Kabi Canada at [Canada\\_Vigilance@fresenius-kabi.com](mailto:Canada_Vigilance@fresenius-kabi.com). Quality concerns can be reported to the Fresenius Kabi Canada Quality Complaints department at [Canada\\_Product\\_Complaints@Fresenius-Kabi.com](mailto:Canada_Product_Complaints@Fresenius-Kabi.com). Fresenius Kabi Canada Customer Service may be contacted toll free at 1-877-821-7724.

Fresenius Kabi Canada is committed to providing you with the highest level of service, product quality and reliability. We apologize for any inconvenience this has caused, and we appreciate your attention to this matter.

Signed by:  
*Anabela Costa*  
Signer Name: Anabela Costa  
Signing Reason: I approve this document  
Signing Time: 05-Feb-26 | 10:21 AM EST  
47888537775647CDA535261EA507915D

Anabela Costa  
Vice President, Scientific Affairs  
Fresenius Kabi Canada Ltd.



**DRUG RECALL – CUSTOMER REPLY FORM**

**Type III - URGENT – Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag) Lots: 440228 00125 and 440228 00135**

**Please reply immediately**

Please complete and return this form to the EMAIL address listed below as confirmation that you have received this notification.

**Email: [Canada\\_Product\\_Complaints@Fresenius-Kabi.com](mailto:Canada_Product_Complaints@Fresenius-Kabi.com)**

Facility Name and Address	
Reply Confirmation Completed By: <i>(Please Print Name)</i>	
Title: <i>(Please Print)</i>	
Phone Number: <i>Including Area Code</i>	

Please check one

<input type="checkbox"/>	We have received the above mentioned letter, understand the instructions and have disseminated this information to our staff and to other centers or facilities, as applicable, and have the following quantity of the affected in our inventory.								
	<table border="1"><thead><tr><th>Material</th><th>Lot</th><th>Quantity</th></tr></thead><tbody><tr><td rowspan="2">Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag))</td><td>440228 00125</td><td></td></tr><tr><td>440228 00135</td><td></td></tr></tbody></table>	Material	Lot	Quantity	Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag))	440228 00125		440228 00135	
Material	Lot	Quantity							
Cefazolin for Injection, USP (SmartPak® Bulk Package 100g/bag))	440228 00125								
	440228 00135								
<input type="checkbox"/>	We have received the above-mentioned letter and have disseminated this information to our staff and to other centers or facilities, as applicable, and DO NOT have any of the listed product/lot in our inventory.								

Signature/Date:

\_\_\_\_\_  
*Print Name, Sign and Date*